Get up to 50% off a prescription of Semaglutide
-
Lose up to 15% of your body fat per week*
-
Get access to Ozempic®, Wegovy® and other weight loss medications†
-
Get approved with this 5-min quiz, no insurance needed
Average reduction in body weight*
Users say this is more effective than anything they’ve ever tried
Average reduction in waist size
Users have achieved lasting weight loss
There's a reason why everyone is talking about Semaglutide. It works.
On average, people on Ozempic or Wegovy lose 15% of their weight in a year or less*.
Lose up to 15% of your body weight
in 3 easy steps
1 Take the quiz
Take the assessment quiz to get pre-approved instantly.
2 Get prescribed
Our doctors will prescribe medication right in the portal - no calls necessary.
3 Get your meds
Get your meds delivered in just a couple days.
Ready to get pre-approved?
Start Your JourneyThousands of people are losing weight with GLP-1 medications
Hear more from our Remote Pharmacy ambassadors, whose success inspired the metabolic weight loss program.
I’ve lost about 18 pounds so far.
“It has been life changing. I was struggling with losing weight, so this has definitely kickstarted my journey."
- Shae W.
Verified Customer
I’m proud of myself for taking this step.
“It’s much faster. You don’t have to wait for a doctor's appointment. It’s more straightforward."
– Michael O.
Verified Customer
Amazing
“So far, in nine days, I’ve lost about five and a half to six pounds. That’s way more than I would’ve done on my own.”
– Elizabeth R
Verified Customer
Revolutionary
Medications
Compounded semaglutide and compounded tirzepatide are GLP-1s that may be prescribed for weight loss if appropriate. These once-weekly shots work by mimicking your body's natural hormones, helping you feel fuller faster and for longer.
GLP-1 Medications Cost Less When You
Buy Directly From Remote Pharmacy
Semaglutide (Compare to Ozempic®) or Tirzepatide (Compare to Mounjaro®)
- Same Day
Appointments! - All-inclusive
Pricing! - No Membership
Fees! - Medication
Included! - Meds delivered in
2 business days - Semaglutide and
Tirzepatide Offered
It’s about biology,
not willpower
Traditional diets don’t work because nearly 70% of weight is genetically determined. Through medication you can work with your body rather than against it - to create safe and long lasting weight loss results.
Take precaution with, and read all warnings concerning, GLP-1s, as they may cause serious side effects, including a risk of thyroid c-cell tumors. Do not use if you or your family have a history of a type of thyroid cancer called MTC (medullary thyroid carcinoma) or MEN 2 (multiple endocrine neoplasia syndrome).
Is Ozempic or Wegovy right for you? Take the quiz
Start Your Journey
Starts at just $199/mo - no insurance needed
The most powerful weight loss program - is yours
What's included?
- Access to Wegovy® or Ozempic®
- No Insurance Needed
- Ongoing Telehealth doctor support
- Includes Medication, supplies & telemed visits
- No Hidden Fees
- Lose up to 15% body fat per week*
- 2-day Expedited Shipping
Wegovy is FDA-approved for weight loss. Ozempic is FDA-approved for type 2 diabetes treatment, but may be prescribed for weight loss.
Frequently Asked Questions
Who can use weight loss medications?
Are GLP-1 medications safe?
How much weight will I lose?
Can I change my dose?
What if I am already on weight loss medication?
Does Remote Pharmacy accept insurance?
Why does my medication look different?
*In a 68-week clinical trial studying once-weekly semaglutide (2.4mg) in patients without diabetes and with BMI ≥30, or BMI ≥27 with a weight-related condition, the average weight loss was 15% when paired with lifestyle intervention (compared to 2.4% with lifestyle intervention alone).
1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. The Journal of clinical investigation, 101(3), 515–520. https://doi.org/10.1172/JCI990
3. Nauck, M. A., Meier, J. J., & Cavender, M. A. (2017). Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation, 136(9), 849-870. https://doi.org/10.1161/CIRCULATIONAHA.117.028136
4. Drucker D. J. (2016). The Cardiovascular Biology of Glucagon-like Peptide-1. Cell metabolism, 24(1), 15–30. https://doi.org/10.1016/j.cmet.2016.06.009
5. Creutzfeldt W. (1979). The incretin concept today. Diabetologia, 16(2), 75–85. https://doi.org/10.1007/BF01225454